📊 Evidence-Based Reference

Hemodialysis Catheter

Haolang Medical U

Compare similar devices

Summary: The hemodialysis catheter by Haolang Medical U is a device used for vascular access in hemodialysis. Key evidence highlights catheter-related thrombosis and infection management strategies.

FDA Clearance Information

Pathway ? 510(k)
Number ? K241581 ↗
Decision Date ? May 16, 2025
Product Code ? MSD Catheter, Hemodialysis, Implanted
Device Class ? Class 2
Evidence ? 0 studies

The hemodialysis catheter by Haolang Medical U was cleared via the FDA 510(k) pathway on May 16, 2025. It is classified as a Class 2 device under product code MSD.

What It Is

The hemodialysis catheter is a medical device designed to provide vascular access for patients undergoing hemodialysis. It facilitates the removal and return of blood to the body during dialysis sessions.

FDA-Cleared Indications

  • Vascular access for hemodialysis.
  • Access for removing and returning blood during hemodialysis treatments.
  • Use as an implanted hemodialysis catheter when dialysis access is required.

Clinical Applications

  • Providing central venous access for patients receiving hemodialysis.
  • Connecting a patient to the dialysis circuit for blood removal and return.
  • Providing dialysis access when an arteriovenous fistula or graft is not available, cannot be used, or is not yet ready.
  • Providing longer-term vascular access when clinically indicated and consistent with the device labeling.

Evidence Summary

The available literature includes 15 studies, comprising various study types such as RCTs and case series, published between 2023 and 2025. These studies focus on thrombosis, infection, and catheter management.

Reported Outcomes

Published studies report that catheter-related thrombosis and bloodstream infections are significant complications associated with hemodialysis catheters. Interventions such as nitric oxide-releasing lock solutions have shown potential in reducing these complications.

Safety Profile

Reported complications include catheter-related thrombosis and bloodstream infections. Studies highlight the importance of managing these risks to improve patient outcomes.

Evidence Limitations

Current evidence is limited by the variability in study designs and small sample sizes. Further research is needed to establish standardized protocols for catheter management and to explore genetic predispositions to complications.

Practical Considerations

  • Catheters are available in different lengths, diameters, lumen configurations, and cuffed or noncuffed designs; selection depends on the patient’s anatomy, access site, dialysis requirements, and manufacturer labeling.
  • Common central venous access sites include the internal jugular, femoral, and subclavian veins. The access site affects infection risk, thrombosis risk, vessel preservation, and future fistula or graft options.
  • Placement and confirmation are generally performed with ultrasound and fluoroscopic or other imaging guidance, using sterile technique. Local anesthesia with or without moderate sedation may be used.
  • MRI compatibility is device-specific. The exact catheter model, labeling, and any associated clamps or connectors should be checked before MRI.
  • Potential complications include infection, bleeding, venous thrombosis or stenosis, catheter malfunction, air embolism, vessel injury, and inadequate dialysis flow. Contraindications and precautions depend on the patient and the specific device labeling.

Frequently Asked Questions

What are the clinical indications for hemodialysis catheter?

The hemodialysis catheter is indicated for vascular access in patients requiring hemodialysis, particularly those with end-stage renal disease.

What outcomes have been reported in clinical studies?

Studies have reported outcomes related to thrombosis and infection management, with some interventions showing promise in reducing these complications.

What complications have been reported?

Safety data from evidence indicate complications such as catheter-related thrombosis and bloodstream infections.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you